News | March 04, 2009

Positron’s Tech-Assist Reduced Radiation Exposure by 50-75 Percent, Study Says

March 4, 2009 - Positron Corp., a Cardiac Molecular Imaging Solutions Company, today released results from an independent study on radiation exposure of technologists administering FDG.

The study was conducted in the Nuclear Medicine Department at Mount Sinai Medical Center in New York, N.Y. by the director of PET, Ash Rafique. The study compared historic whole body and ring readings using a traditional syringe shield compared to Positron’s Tech-Assist device. The results showed a reduction in whole body badge exposure by 50–75 percent and ring badge reductions of 40-55 percent, compared to previous month’s data.

Positron’s Tech-Assist is a heavy-duty syringe shield (PIG) mounted on a portable cart system. This system is designed to reduce or limit exposure, heavy lifting injuries and repetitive motion injuries that occur during nuclear medicine injection applications. The Tech-Assist was designed with the ALARA principles of time, distance, and shielding in mind. The Tech-Assist utilizes tungsten for all shielding. The cart enables the user to transport the PIG to and from the injection room with ease and adjusts to various height levels allowing for the injection of ambulatory or supine patients. . The variable injection head rotates 360° allowing for left or right arm injections and hinges to four different angles creating multiple loading or injecting positions. In additional to significant reduction in radiation exposure the Tech-Assist will reportedly improve the comfort and ease of the injection process for the patient as well as for the technologist/nurse.

For more information:

Related Content

CZT SPECT camera detectors offered by GE.

A display of CZT SPECT gamma camera detectors at RSNA 2016. These detectors are more sensitive than those used in older cameras, allowing for faster scans or lower radiation dose. 

Feature | Nuclear Imaging | September 19, 2017 | Dave Fornell
Cardiac nuclear myocardial perfusion imaging (MPI) has been a mature area of imaging for years, but has recently star
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Videos | Nuclear Imaging | August 24, 2017
Randy Thompson, M.D., attending cardiologist, St.
cardiac nuclear myocardial perfusion imaging (MIP) exam guidelines for women
News | Nuclear Imaging | June 15, 2017
June 15, 2017 — The American Society of Nuclear Cardiology (ASNC) has published an updated consensus statement on evi
Videos | Nuclear Imaging | April 28, 2017
David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American S
IBA Molecular, acquisition, Mallinckrodt Nuclear Imaging, nuclear imaging
News | Nuclear Imaging | January 30, 2017
IBA Molecular has successfully completed its acquisition of Mallinckrodt Nuclear Imaging, announced in August 2016,...
Medrad Intego PET Infusion System, recall
News | Nuclear Imaging | January 12, 2017
January 12, 2017 — Bayer Healthcare has initiated a recall of all its Medrad Intego PET Infusion System Source Admini
Nuclear cardiology, dose reduction, myocardial perfusion imaging
News | Nuclear Imaging | January 05, 2017
January 5, 2017 — Working in concert, the American Society of Nuclear Cardiology (ASNC), the Intersocietal Accreditat
PET, F-18 florbetaben, cardiac amyloidosis, Princess Alexandria Hospital

In a pilot study, F-18-florbetaben PET imaging appeared promising for differentiating between cardiac amyloidosis and hypertensive heart disease. Image courtesy of W. Phillip Law/Princess Alexandra Hospital, Brisbane, Australia.

News | Nuclear Imaging | December 06, 2016
Researchers at Princess Alexandra Hospital, Brisbane, Australia, have demonstrated that cardiac amyloidosis (abnormal...
Overlay Init